Insights into the current status of privileged N-heterocycles as antileishmanial agents
Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These...
Gespeichert in:
Veröffentlicht in: | Molecular diversity 2020-05, Vol.24 (2), p.525-569 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 569 |
---|---|
container_issue | 2 |
container_start_page | 525 |
container_title | Molecular diversity |
container_volume | 24 |
creator | Razzaghi-Asl, Nima Sepehri, Saghi Ebadi, Ahmad Karami, Pari Nejatkhah, Negin Johari-Ahar, Mohammad |
description | Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged
N
-heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed.
Graphical abstract |
doi_str_mv | 10.1007/s11030-019-09953-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2216285254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2215418181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</originalsourceid><addsrcrecordid>eNp9kF9LHDEUxYNUuqv2C_hQAn3pS_TeyWT-PBaxKkh9UfQtZDN3dmeZndnmZgS_fbOuVuhDSSCB-zsnOUeIU4QzBCjPGRE0KMBaQV0brfIDMUdTamUAnz6lu65QYV3jTBwxrwGSDPVnMdMIWWVMNRePNwN3y1Vk2Q1xlHFF0k8h0BAlRxcnlmMrt6F77npaUiN_qRVFCqN_8T2xdGkPMc06Xm3c0LleumUS84k4bF3P9OXtPBYPPy_vL67V7d3VzcWPW-V1aaLyCF4X1PpFk2ntK3KGoIW2zFxZFeXC56AbyrWGrGjyNuVpFpi3hakr8nVV6GPxfe-7DePviTjaTcee-t4NNE5sswyLFDUzeUK__YOuxykM6Xc7yuRYpZWobE_5MDIHam1Kv3HhxSLYXe12X7tNtdvX2u3O-uub9bTYUPNX8t5zAvQe4DQalhQ-3v6P7R_VE42j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2215418181</pqid></control><display><type>article</type><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</creator><creatorcontrib>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</creatorcontrib><description>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged
N
-heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed.
Graphical abstract</description><identifier>ISSN: 1381-1991</identifier><identifier>EISSN: 1573-501X</identifier><identifier>DOI: 10.1007/s11030-019-09953-4</identifier><identifier>PMID: 31028558</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Animals ; Antiprotozoal Agents - chemistry ; Antiprotozoal Agents - pharmacology ; Antiprotozoal Agents - therapeutic use ; Biochemistry ; Biomedical and Life Sciences ; Comprehensive Review ; Health risks ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; Heterocyclic Compounds - therapeutic use ; Humans ; Inspection ; Leishmania - drug effects ; Leishmaniasis - drug therapy ; Life Sciences ; Organic Chemistry ; Pharmacy ; Polymer Sciences ; Public health ; Toxicity</subject><ispartof>Molecular diversity, 2020-05, Vol.24 (2), p.525-569</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Springer Nature Switzerland AG 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</citedby><cites>FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</cites><orcidid>0000-0001-6127-2497</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11030-019-09953-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11030-019-09953-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31028558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Razzaghi-Asl, Nima</creatorcontrib><creatorcontrib>Sepehri, Saghi</creatorcontrib><creatorcontrib>Ebadi, Ahmad</creatorcontrib><creatorcontrib>Karami, Pari</creatorcontrib><creatorcontrib>Nejatkhah, Negin</creatorcontrib><creatorcontrib>Johari-Ahar, Mohammad</creatorcontrib><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><title>Molecular diversity</title><addtitle>Mol Divers</addtitle><addtitle>Mol Divers</addtitle><description>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged
N
-heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed.
Graphical abstract</description><subject>Animals</subject><subject>Antiprotozoal Agents - chemistry</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Comprehensive Review</subject><subject>Health risks</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Heterocyclic Compounds - therapeutic use</subject><subject>Humans</subject><subject>Inspection</subject><subject>Leishmania - drug effects</subject><subject>Leishmaniasis - drug therapy</subject><subject>Life Sciences</subject><subject>Organic Chemistry</subject><subject>Pharmacy</subject><subject>Polymer Sciences</subject><subject>Public health</subject><subject>Toxicity</subject><issn>1381-1991</issn><issn>1573-501X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kF9LHDEUxYNUuqv2C_hQAn3pS_TeyWT-PBaxKkh9UfQtZDN3dmeZndnmZgS_fbOuVuhDSSCB-zsnOUeIU4QzBCjPGRE0KMBaQV0brfIDMUdTamUAnz6lu65QYV3jTBwxrwGSDPVnMdMIWWVMNRePNwN3y1Vk2Q1xlHFF0k8h0BAlRxcnlmMrt6F77npaUiN_qRVFCqN_8T2xdGkPMc06Xm3c0LleumUS84k4bF3P9OXtPBYPPy_vL67V7d3VzcWPW-V1aaLyCF4X1PpFk2ntK3KGoIW2zFxZFeXC56AbyrWGrGjyNuVpFpi3hakr8nVV6GPxfe-7DePviTjaTcee-t4NNE5sswyLFDUzeUK__YOuxykM6Xc7yuRYpZWobE_5MDIHam1Kv3HhxSLYXe12X7tNtdvX2u3O-uub9bTYUPNX8t5zAvQe4DQalhQ-3v6P7R_VE42j</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Razzaghi-Asl, Nima</creator><creator>Sepehri, Saghi</creator><creator>Ebadi, Ahmad</creator><creator>Karami, Pari</creator><creator>Nejatkhah, Negin</creator><creator>Johari-Ahar, Mohammad</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6127-2497</orcidid></search><sort><creationdate>20200501</creationdate><title>Insights into the current status of privileged N-heterocycles as antileishmanial agents</title><author>Razzaghi-Asl, Nima ; Sepehri, Saghi ; Ebadi, Ahmad ; Karami, Pari ; Nejatkhah, Negin ; Johari-Ahar, Mohammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-c10c36efcbd233c8ea5e0f0f72a7867bc403de433026d4f381db14f6598ec9863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antiprotozoal Agents - chemistry</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Comprehensive Review</topic><topic>Health risks</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Heterocyclic Compounds - therapeutic use</topic><topic>Humans</topic><topic>Inspection</topic><topic>Leishmania - drug effects</topic><topic>Leishmaniasis - drug therapy</topic><topic>Life Sciences</topic><topic>Organic Chemistry</topic><topic>Pharmacy</topic><topic>Polymer Sciences</topic><topic>Public health</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Razzaghi-Asl, Nima</creatorcontrib><creatorcontrib>Sepehri, Saghi</creatorcontrib><creatorcontrib>Ebadi, Ahmad</creatorcontrib><creatorcontrib>Karami, Pari</creatorcontrib><creatorcontrib>Nejatkhah, Negin</creatorcontrib><creatorcontrib>Johari-Ahar, Mohammad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular diversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Razzaghi-Asl, Nima</au><au>Sepehri, Saghi</au><au>Ebadi, Ahmad</au><au>Karami, Pari</au><au>Nejatkhah, Negin</au><au>Johari-Ahar, Mohammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the current status of privileged N-heterocycles as antileishmanial agents</atitle><jtitle>Molecular diversity</jtitle><stitle>Mol Divers</stitle><addtitle>Mol Divers</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>24</volume><issue>2</issue><spage>525</spage><epage>569</epage><pages>525-569</pages><issn>1381-1991</issn><eissn>1573-501X</eissn><abstract>Leishmania, one of the most important neglected tropical diseases, is endemic in several regions of the world and hence regarded as a serious threat to public health. Major difficulties with current chemotherapeutic agents raise issues such as toxicity, resistance, cost and other side effects. These issues necessitate development of potentially new chemical entities against diverse leishmanial species. Numerous natural and synthetic new antileishmanial molecules have been described for disease management. Careful inspection of scientific reports revealed that considerable amount of promising antileishmanial agents belonged to the nitrogen-containing heterocycles such as quinoline, triazole, pyrazole, imidazole, indole, pyrimidine, β-carboline, quinoxaline, quinazoline and benzimidazole. In this regard, enormous chemical data provide the opportunity for systematic elucidation of structural requirements against different leishmanial species. Within this representation, insights into the current status of privileged
N
-heterocycles as antileishmanial agents with particular emphasis on structure activity relationships are reviewed.
Graphical abstract</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31028558</pmid><doi>10.1007/s11030-019-09953-4</doi><tpages>45</tpages><orcidid>https://orcid.org/0000-0001-6127-2497</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1381-1991 |
ispartof | Molecular diversity, 2020-05, Vol.24 (2), p.525-569 |
issn | 1381-1991 1573-501X |
language | eng |
recordid | cdi_proquest_miscellaneous_2216285254 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Animals Antiprotozoal Agents - chemistry Antiprotozoal Agents - pharmacology Antiprotozoal Agents - therapeutic use Biochemistry Biomedical and Life Sciences Comprehensive Review Health risks Heterocyclic Compounds - chemistry Heterocyclic Compounds - pharmacology Heterocyclic Compounds - therapeutic use Humans Inspection Leishmania - drug effects Leishmaniasis - drug therapy Life Sciences Organic Chemistry Pharmacy Polymer Sciences Public health Toxicity |
title | Insights into the current status of privileged N-heterocycles as antileishmanial agents |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20current%20status%20of%20privileged%20N-heterocycles%20as%20antileishmanial%20agents&rft.jtitle=Molecular%20diversity&rft.au=Razzaghi-Asl,%20Nima&rft.date=2020-05-01&rft.volume=24&rft.issue=2&rft.spage=525&rft.epage=569&rft.pages=525-569&rft.issn=1381-1991&rft.eissn=1573-501X&rft_id=info:doi/10.1007/s11030-019-09953-4&rft_dat=%3Cproquest_cross%3E2215418181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2215418181&rft_id=info:pmid/31028558&rfr_iscdi=true |